ORGO Q2 2024 Earnings — Organogenesis Holdings Inc. Revenue & Financial Results | Market Cap Arena

ORGOOrganogenesis Holdings Inc.

$355M

Q2 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$130M+11.0% YoY

Gross Profit

$101M77.6% margin

Operating Income

-$14M-10.7% margin

Net Income

-$17M-13.1% margin

EPS (Diluted)

$-0.13

QoQ Revenue Growth

+18.4%

Cash Flow

Operating Cash Flow

$5M

Free Cash Flow

$3M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$443M

Total Liabilities

$180M

Stockholders' Equity

$264M

Cash & Equivalents

$90M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$130M	$117M	+11.0%
Gross Profit	$101M	$91M	+11.0%
Operating Income	-$14M	$10M	-242.6%
Net Income	-$17M	$5M	-420.6%

Revenue Segments

Advanced Wound care

$123M95%

Surgical and Sports Medicine

$7M5%